Bioptimus has emerged from stealth following a seed funding round of $35 million. Under the leadership of Professor Jean-Philippe Vert, PhD, Bioptimus combines a world-class team of scientists from Owkin and Google DeepMind alumni to transform biology with cutting-edge AI foundation model technologies that capture the various scales of biology.
This funding round is led by Sofinnova Partners, with Bpifrance Large Venture and additional support from global funds based in France, including Frst and multistage VC Cathay Innovation. And top global tech investors Headline, Hummingbird, NJF Capital, Owkin and Top Harvest Capital, and notable tech entrepreneur Xavier Niel, have joined the round to create a global leader in AI for biology in France.
Bioptimus will benefit from Owkin’s data generation capabilities, and federated global access to multimodal patient data sourced from leading academic hospitals worldwide, and a best-in-class, scalable and secure computing environment from Amazon Web Services (AWS). And fueled by an abundance of data from all scales and modalities, this gives the power to create computational representations that establish a strong differentiation against models trained solely on public datasets and a single data modality that cannot capture the full diversity of biology.
KEY QUOTES:
“The application of foundation models and generative AI to biology is set to have a profound impact in science. By harnessing the power of foundation models and advanced algorithms trained on massive amounts of biological and multimodal data across scales, we aim to capture the laws of biology that have hitherto remained too complex to be properly understood. This holistic understanding of biology across scales will be critical to accelerate biomedical and environmental science.”
- Professor Jean-Philippe Vert, PhD, co-founder and CEO of Bioptimus, Chief R&D Officer of Owkin and former Research Lead at Google Brain
“Foundation models in biology are game-changers. They unlock unprecedented potential to personalize medicine, capturing the uniqueness of each individual while harnessing the collective knowledge of all. Bioptimus stands out by seamlessly blending unparalleled data resources and access, elite talent, and extensive computational power. Together with Sofinnova’s deep expertise in life sciences and our expansive network, we’re poised to redefine the future of the industry.”
- Edward Kliphuis, Partner at Sofinnova Partners
“Founded on the ambition to make a quantum leap in our understanding of the complexity of human biology and bringing together a top team of accomplished experts in the fields of data science and generative AI, Bioptimus holds the promise to go even deeper in the analysis of patients’ data across multiple levels and help unveil biological connections hitherto unthought-of. We at Bpifrance are delighted to team-up with such an impressive team and group of investors and support the development of a category defining company that has the potential to disrupt many R&D activities.”
- Laurent Higueret, Senior Investment Director at Bpifrance Large Venture
